|
市場調查報告書
PCI 與血栓溶解療法
Trends in PCI - PCI vs. Thrombolysis: The Debate
| 出版商 |
Datamonitor |
| 出版日期 |
2004年12月 |
商品編碼 |
25946 |
| 內容資訊 |
英文 31 Pages |
| 價格 |
|
|
本報告已在2011年07月19日停止出版。
使用藥物分解支架成形術的 PCI （經皮冠動脈成形術）是標準的一種治療法。而在未來生物分解性支架將成為標準的情況下，PCI 與血栓溶解療法的爭論還是以前者佔上風。
擅長多領域分析的英國專業公司 Datamonitor Corporation（總公司：倫敦），調查分析了 PCI 與血栓溶解療法後，出版了一本綜合報告書 "Trends in PCI - PCI vs. Thrombolysis: The Debate"。
報告書內容包括：藥物分解支架的發展、PCI 主要企業的生物分解支架拓展對市場的影響、PCI 與血栓溶解療法相關爭論、血栓溶解療法開始前的時間、遠隔轉送等等。全書含圖表，內容綱要摘記如下：
摘要
PCI 市場動向
- PCI 市場
- 藥物分解支架的發展
- 藥物分解支架的成功
- 藥物分解支架的 C/P
- 藥物分解支架成為標準
- 臨床實驗相關最新情報
- 藥物分解支架的安全性與副作用問題
- 償還相關最新情報
- 新加入企業
- 未來市場
PCI 與血栓溶解療法
- PCI領先
- 血栓溶解療法開始前的時間
- 遠隔與轉送時間
- 入院前的血栓溶解療法
- 新研發
- 總論
附錄
圖
Introduction
- Drug-eluting stents have become the gold standard in PCI procedures; it is
up for debate as to whether biodegradable stents become the future gold
standard. The debate about PCI vs thrombolysis still continues, however
opinion seems to be falling firmly on the side of PCI.
Scope of this report
- Market overview and review of the rise of drug eluting stents to
gold-standard status, with an update on clinical trials and reimbursement
status
- Identify the key players in the PCI drug-eluting stent market and
understand how this is likely to change with the advent of biodegradable
stents
- Follow the debate on PCI vs. thrombolysis and understand why opinion
leaders seem to favor PCI
- Understand the critical issue around time-to-needle and remote transfer
Research and analysis highlights
- The drug-eluting stent seems to be the device for the future by solving
(and promising to solve) one of the largest problems of interventional
coronary treatment: restenosis. Opinion leaders interviewed by Datamonitor
in 2004 suggest that the use of drug-eluting stents has reached 9095% of the
stent market both in the US and Europe.
- It is now thought that even with the additional delay, transfer of
patients for PCI is associated with better outcomes than treating with
thrombolysis at the local hospital.
- When primary PCI cannot be provided readily and transfer is necessary,
intravenous thrombolysis may be a better choice for patients seen early
(within the first two hours), especially if it can be provided in a
pre-hospital setting. This does not preclude subsequent transfer to an
interventional center.
Key reasons to read this report
- Understand the reasons for the success of drug-eluting stents and their
rise to becoming the gold-standard treatment
- Identify the key players in the PCI drug-eluting stent market and
understand how the market will evolve with the advent of biodegradable
stents
- Understand why opinion leaders seem to favor PCI over thrombolysis and the
critical issue around time-to-needle and remote transfer
ABOUT DATAMONITOR HEALTHCARE
- About the Cardiovascular pharmaceutical analysis team
EXECUTIVE SUMMARY
- Introduction
- Scope and coverage of this Brief
- Key findings about the topic
PERCUTANEOUS CORONARY INTERVENTION MARKET DYNAMICS
- The PCI market
- Evolution to drug-eluting stents
- Success of the drug-eluting stent
- Cost effectiveness of drug-eluting stents
- The drug-eluting stent gold standard
- Latest clinical trial update
- Safety and side-effect issues with drug-eluting stents
- Stents and the use of adjunctive therapy
- Reimbursement update
- New entrants
- Biodegradable stent technology
- Future market
PCI VS. THROMBOLYSIS
- PCI is the way forward
- Time-to-needle
- Remoteness and transfer time
- Pre-hospital thrombolysis: the next step?
- New developments
- Conclusion
APPENDIX
- Contributing experts
- Bibliography
- Other Clinical Data
- Research methodology
- Disclaimer
- List of Tables
- Table 1: Comparison of cost of bare-metal and drug-eluting stents
- Table 2: Drug-eluting stents marketed or in development
- Table 3: Price comparisons of adjunctive therapies
- List of Figures
- Figure 1: Advances in PCI have improved patient outcomes (US data)
- Figure 2: Drug-eluting stents have further improved patient outcomes
- Figure 3: Breakdown of treatment time and mortality rate
|
